Biotech · Public company · Foster City, CA, US

Mirum Pharmaceuticals, Inc.

Ticker MIRM · SEC CIK 0001759425

Track this companyFree. Adds Mirum Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials259 recruiting or active

Pipeline programs30From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline30

Blinded CDCA 250 mg TIDPhase 3 · CTXClinicalTrials.gov · fetched Nov 12, 2026
Brelovitug 300 mgPhase 3 · Chronic Hepatitis D InfectionClinicalTrials.gov · fetched Nov 12, 2026
Brelovitug 900 mgPhase 3 · Chronic Hepatitis D InfectionClinicalTrials.gov · fetched Nov 12, 2026
CDCA Weight-Based Dose TIDPhase 3 · CTXClinicalTrials.gov · fetched Nov 12, 2026
Cholic acidPhase 3 · Inborn Errors of Bile Acid SynthesisClinicalTrials.gov · fetched Nov 12, 2026
Cholic AcidPhase 3 · Bile Acid Synthesis DefectClinicalTrials.gov · fetched Nov 12, 2026
Cholic AcidsPhase 3 · Infantile Refsum's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Delayed Treatment with Brelovitug 300mgPhase 3 · Chronic Hepatitis D InfectionClinicalTrials.gov · fetched Nov 12, 2026
MaralixibatPhase 3 · Progressive Familial Intrahepatic Cholestasis (PFIC)ClinicalTrials.gov · fetched Nov 12, 2026
MaralixibatPhase 3 · Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)ClinicalTrials.gov · fetched Nov 12, 2026
Open-Label CDCA 250 mg TIDPhase 3 · CTXClinicalTrials.gov · fetched Nov 12, 2026
Rescue Medication CDCA 250 mg TIDPhase 3 · CTXClinicalTrials.gov · fetched Nov 12, 2026
High dose of MRM-3379Phase 2 · Fragile X SyndromeClinicalTrials.gov · fetched Nov 12, 2026
Low dose of MRM-3379Phase 2 · Fragile X SyndromeClinicalTrials.gov · fetched Nov 12, 2026
Low dose of MRM-3379 Open-LabelPhase 2 · Fragile X SyndromeClinicalTrials.gov · fetched Nov 12, 2026
LUM001 (Maralixibat)Phase 2 · Alagille SyndromeClinicalTrials.gov · fetched Nov 12, 2026
LUM001 (Maralixibat)Phase 2 · Progressive Familial Intrahepatic Cholestasis (PFIC)ClinicalTrials.gov · fetched Nov 12, 2026
MaralixibatPhase 2 · Progressive Familial Intrahepatic CholestasisClinicalTrials.gov · fetched Nov 12, 2026
MaralixibatPhase 2 · Biliary AtresiaClinicalTrials.gov · fetched Nov 12, 2026
MaralixibatPhase 2 · Cholestatic Liver DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Middle Dose of MRM-3379Phase 2 · Fragile X SyndromeClinicalTrials.gov · fetched Nov 12, 2026
SHP626Phase 2 · Non-Alcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
VolixibatPhase 2 · Primary Sclerosing CholangitisClinicalTrials.gov · fetched Nov 12, 2026
VolixibatPhase 2 · Intrahepatic Cholestasis of PregnancyClinicalTrials.gov · fetched Nov 12, 2026
VolixibatPhase 2 · Primary Biliary CholangitisClinicalTrials.gov · fetched Nov 12, 2026
[14C]-MRM-3379Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
BrelovitugChronic Hepatitis, Delta VirusClinicalTrials.gov · fetched Nov 12, 2026
CholbamBile Acid Synthesis DisordersClinicalTrials.gov · fetched Nov 12, 2026
LivmarliAlagille SyndromeClinicalTrials.gov · fetched Nov 12, 2026
maralixibatAlagille SyndromeClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379PHASE1 · COMPLETED · started May 29, 2026ClinicalTrials.gov NCT07712718 · fetched Nov 12, 2026
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)PHASE3 · ACTIVE_NOT_RECRUITING · started Jan 14, 2026ClinicalTrials.gov NCT07298330 · fetched Nov 12, 2026
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)PHASE2 · RECRUITING · started Nov 22, 2025ClinicalTrials.gov NCT07209462 · fetched Nov 12, 2026
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta InfectionPHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Mar 25, 2025ClinicalTrials.gov NCT06907290 · fetched Nov 12, 2026
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)PHASE3 · ACTIVE_NOT_RECRUITING · started Oct 14, 2024ClinicalTrials.gov NCT06553768 · fetched Nov 12, 2026
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)RECRUITING · started Sep 21, 2023ClinicalTrials.gov NCT06193928 · fetched Nov 12, 2026
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 22, 2021ClinicalTrials.gov NCT05050136 · fetched Nov 12, 2026
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).PHASE2 · COMPLETED · started Sep 9, 2021ClinicalTrials.gov NCT04729751 · fetched Nov 12, 2026
Evaluation of Maralixibat in Biliary Atresia Response Post-KasaiPHASE2 · COMPLETED · started Jul 8, 2021ClinicalTrials.gov NCT04524390 · fetched Nov 12, 2026
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening ProgramENROLLING_BY_INVITATION · started May 10, 2021ClinicalTrials.gov NCT05368038 · fetched Nov 12, 2026
A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)PHASE2 · TERMINATED · started Jan 4, 2021ClinicalTrials.gov NCT04718961 · fetched Nov 12, 2026
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 18, 2020ClinicalTrials.gov NCT04663308 · fetched Nov 12, 2026
Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)PHASE3 · COMPLETED · started Jan 31, 2020ClinicalTrials.gov NCT04270682 · fetched Nov 12, 2026
MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat StudyPHASE2 · COMPLETED · started Jan 16, 2020ClinicalTrials.gov NCT04168385 · fetched Nov 12, 2026
An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)PHASE3 · COMPLETED · started Jan 8, 2020ClinicalTrials.gov NCT04185363 · fetched Nov 12, 2026
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)PHASE3 · COMPLETED · started Jul 9, 2019ClinicalTrials.gov NCT03905330 · fetched Nov 12, 2026
The REPLACE Registry for Cholbam® (Cholic Acid)ACTIVE_NOT_RECRUITING · started Jul 10, 2017ClinicalTrials.gov NCT03115086 · fetched Nov 12, 2026
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)PHASE2 · TERMINATED · started Oct 24, 2016ClinicalTrials.gov NCT02787304 · fetched Nov 12, 2026
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille SyndromePHASE2 · COMPLETED · started Mar 16, 2015ClinicalTrials.gov NCT02117713 · fetched Nov 12, 2026
Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic CholestasisPHASE2 · COMPLETED · started Mar 1, 2014ClinicalTrials.gov NCT02057718 · fetched Nov 12, 2026
Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid SynthesisPHASE3 · COMPLETED · started Apr 1, 2010ClinicalTrials.gov NCT01115582 · fetched Nov 12, 2026
Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid SynthesisPHASE3 · COMPLETED · started Jan 1, 2010ClinicalTrials.gov NCT01438411 · fetched Nov 12, 2026
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic AcidPHASE3 · COMPLETED · started Jan 1, 1992ClinicalTrials.gov NCT00007020 · fetched Nov 12, 2026
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)APPROVED_FOR_MARKETINGClinicalTrials.gov NCT04530994 · fetched Nov 12, 2026
EXPANDED-ACCESS PROGRAM FOR THE TREATMENT OF CHRONIC HEPATITIS D WITH BRELOVITUGAVAILABLEClinicalTrials.gov NCT07922733 · fetched Nov 12, 2026

SEC filings12

8-K · 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 26, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 13, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Sep 28, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Sep 8, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 18, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 18, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026